Ausdal Financial Partners Inc. Takes Position in Guardant Health, Inc. (NASDAQ:GH)

Ausdal Financial Partners Inc. bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, HoldingsChannel reports. The firm bought 7,000 shares of the company’s stock, valued at approximately $214,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Guardant Health during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. acquired a new stake in Guardant Health during the fourth quarter worth $43,000. Kimelman & Baird LLC purchased a new stake in Guardant Health in the fourth quarter valued at $58,000. Quantbot Technologies LP acquired a new position in shares of Guardant Health in the 4th quarter valued at $80,000. Finally, Jones Financial Companies Lllp grew its holdings in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after purchasing an additional 817 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on GH shares. Canaccord Genuity Group lifted their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Piper Sandler lifted their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. The Goldman Sachs Group upped their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Barclays assumed coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Morgan Stanley boosted their price objective on Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of “Buy” and a consensus target price of $48.95.

Guardant Health Stock Performance

NASDAQ:GH opened at $43.14 on Friday. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The stock has a market cap of $5.32 billion, a P/E ratio of -12.12 and a beta of 1.50. The stock has a 50-day simple moving average of $44.66 and a 200-day simple moving average of $34.24.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, equities research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.